We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

0.02% more ownership

Funds ownership: 0.79% → 0.82% (+0.02%)

0% more funds holding

Funds holding: 115 → 115 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

23% less capital invested

Capital invested by funds: $232M → $179M (-$53.7M)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $486K

Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
45
Reduced
30
Closed
20
Calls
$1K
Puts
$486K
Net Calls
-$485K
Net Calls Change
+$244K

Top Buyers

1
BI
BVF Inc
California
+$10.4M
2
BlackRock
BlackRock
New York
+$5.26M
3
PM
Prosight Management
Texas
+$4.74M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.95M
5
American Century Companies
American Century Companies
Missouri
+$2.57M

Top Sellers

1
O
OrbiMed
New York
-$14.3M
2
Morgan Stanley
Morgan Stanley
New York
-$5.2M
3
Millennium Management
Millennium Management
New York
-$4.42M
4
EI
EAM Investors
California
-$3.56M
5
AL
AJO LP
Pennsylvania
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
26
GSA Capital Partners
United Kingdom
$1.37M +$1.51M +3,165 +1,514%
CWM
27
CIBC World Markets
New York
$1.27M -$551K -1,158 -27%
FQ
28
First Quadrant
California
$1.26M -$14.3K -30 -1%
Charles Schwab
29
Charles Schwab
California
$1.09M +$849K +1,785 +200%
AQR Capital Management
30
AQR Capital Management
Connecticut
$1.03M -$1.27M -2,663 -51%
Cerity Partners
31
Cerity Partners
New York
$965K – – –
SIM
32
Spark Investment Management
New York
$941K +$1.1M +2,321 New
Assenagon Asset Management
33
Assenagon Asset Management
Luxembourg
$934K +$1.1M +2,303 New
Baird Financial Group
34
Baird Financial Group
Wisconsin
$876K +$28.6K +60 +3%
Allianz Asset Management
35
Allianz Asset Management
Germany
$863K -$102K -215 -9%
MWNA
36
Marshall Wace North America
New York
$816K -$1.18M -2,473 -55%
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$788K +$664K +1,396 +257%
VEA
38
Virtus ETF Advisers
New York
$773K +$160K +336 +21%
AllianceBernstein
39
AllianceBernstein
Tennessee
$717K +$211K +443 +33%
Morgan Stanley
40
Morgan Stanley
New York
$641K -$5.2M -10,937 -87%
PIM
41
Platinum Investment Management
Australia
$630K – – –
Two Sigma Advisers
42
Two Sigma Advisers
New York
$597K +$123K +258 +21%
Deutsche Bank
43
Deutsche Bank
Germany
$559K -$488K -1,025 -43%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$551K -$512K -1,076 -44%
SO
45
STRS Ohio
Ohio
$532K +$69K +145 +12%
Los Angeles Capital Management
46
Los Angeles Capital Management
California
$513K +$601K +1,264 New
AIM
47
Assured Investment Management
New York
$500K +$587K +1,233 New
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$490K -$113K -238 -16%
Wells Fargo
49
Wells Fargo
California
$484K +$116K +243 +26%
Creative Planning
50
Creative Planning
Kansas
$451K +$30K +63 +6%
1
2
3 4 5

PVLA Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.

Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
  • The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q2 2018.